Cargando…

Targeting of Both the c-Met and EGFR Pathways Results in Additive Inhibition of Lung Tumorigenesis in Transgenic Mice

EGFR and c-Met are both overexpressed in lung cancer and initiate similar downstream signaling, which may be redundant. To determine how frequently ligands that initiate signaling of both pathways are found in lung cancer, we analyzed serum for hepatocyte growth factor (HGF), transforming growth fac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stabile, Laura P., Rothstein, Mary E., Keohavong, Phouthone, Lenzner, Diana, Land, Stephanie R., Gaither-Davis, Autumn L., Kim, K. Jin, Kaminski, Naftali, Siegfried, Jill M.
Formato:	Texto
Lenguaje:	English
Publicado:	MDPI 2010
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049550/ https://www.ncbi.nlm.nih.gov/pubmed/21390244 http://dx.doi.org/10.3390/cancers2042153

Ejemplares similares

Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers
por: Liu, Yang, et al.
Publicado: (2007)

HGF-independent Potentiation of EGFR Action by c-Met
por: Dulak, Austin M., et al.
Publicado: (2011)

Nicotine signals through muscle-type and neuronal nicotinic acetylcholine receptors in both human bronchial epithelial cells and airway fibroblasts
por: Carlisle, Diane L, et al.
Publicado: (2004)

BDNF Val66Met Polymorphism Influences Age Differences in Microstructure of the Corpus Callosum
por: Kennedy, Kristen M., et al.
Publicado: (2009)

Gastrin-releasing peptide receptor expression in non-cancerous bronchial epithelia is associated with lung cancer: a case-control study
por: Egloff, Ann Marie, et al.
Publicado: (2012)

MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition
por: Ortiz-Zapater, Elena, et al.
Publicado: (2017)

EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers
por: Garofalo, Michela, et al.
Publicado: (2011)

MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells
por: Presutti, Dario, et al.
Publicado: (2015)

Brain-Derived Neurotrophic Factor Val66Met and Blood Glucose: A Synergistic Effect on Memory
por: Raz, Naftali, et al.
Publicado: (2008)

EGFR/Met association regulates EGFR TKI resistance in breast cancer
por: Mueller, Kelly L, et al.
Publicado: (2010)

Norcantharidin Inhibits cell growth by suppressing the expression and phosphorylation of both EGFR and c-Met in human colon cancer cells
por: Qiu, Peiju, et al.
Publicado: (2017)

ROR1 is a pseudokinase that is crucial for MET-driven tumorigenesis
por: Lazzari, Luca, et al.
Publicado: (2013)

Circular RNA encoded MET variant promotes glioblastoma tumorigenesis
por: Zhong, Jian, et al.
Publicado: (2023)

Regulation of EGFR signalling by palmitoylation and its role in tumorigenesis
por: Kadry, Yasmin A., et al.
Publicado: (2021)

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
por: Baldacci, Simon, et al.
Publicado: (2017)

Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer
por: Miranda, Oshin, et al.
Publicado: (2018)

Involvement of lipid rafts in adhesion-induced activation of Met and EGFR
por: Lu, Ying-Che, et al.
Publicado: (2011)

Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
por: Nanjo, Shigeki, et al.
Publicado: (2013)

Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer
por: Park, Silvia, et al.
Publicado: (2015)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
por: Zhang, Zhe, et al.
Publicado: (2019)

Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2020)

EGFR-mediated Macrophage Activation Promotes Colitis-associated Tumorigenesis
por: Hardbower, Dana M., et al.
Publicado: (2017)

The EGFR-HSF1 axis accelerates the tumorigenesis of pancreatic cancer
por: Qian, Weikun, et al.
Publicado: (2021)

Precision immunointerception of EGFR-driven tumorigenesis for lung cancer prevention
por: Pan, Jing, et al.
Publicado: (2023)

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
por: Wang, Qiming, et al.
Publicado: (2019)

Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers
por: Linklater, Erik S., et al.
Publicado: (2016)

Expression level of EGFR and MET receptors regulates invasiveness of melanoma cells
por: Pietraszek‐Gremplewicz, Katarzyna, et al.
Publicado: (2019)

Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer
por: Tang, Z, et al.
Publicado: (2008)

NF-κB1 p105 suppresses lung tumorigenesis through the Tpl2 kinase but independently of its NF-κB function
por: Sun, Fan, et al.
Publicado: (2015)

Strain difference in transgene-induced tumorigenesis and suppressive effect of ionizing radiation
por: Dutta, Bibek, et al.
Publicado: (2020)

Honokiol suppresses lung tumorigenesis by targeting EGFR and its downstream effectors
por: Song, Jung Min, et al.
Publicado: (2016)

EGFR Induces E2F1-Mediated Corticotroph Tumorigenesis
por: Araki, Takako, et al.
Publicado: (2017)

Combination of Selected MET and EGFR Inhibitors Decreases Melanoma Cells’ Invasive Abilities
por: Simiczyjew, Aleksandra, et al.
Publicado: (2019)

Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET
por: Neijssen, Joost, et al.
Publicado: (2021)

Pten-NOLC1 Fusion Promotes Cancers Involving MET and EGFR Signalings
por: Luo, Jian-Hua, et al.
Publicado: (2020)

Combinations of EGFR and MET inhibitors reduce proliferation and invasiveness of mucosal melanoma cells
por: Simiczyjew, Aleksandra, et al.
Publicado: (2023)

ANO1/TMEM16A interacts with EGFR and correlates with sensitivity to EGFR-targeting therapy in head and neck cancer
por: Bill, Anke, et al.
Publicado: (2015)

Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification
por: Tanizaki, J, et al.
Publicado: (2011)

Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC
por: Wang, Kaiwen, et al.
Publicado: (2023)

Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation
por: Nakade, Junya, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_0o0jmj85efu5lghil5maar3hvj